Area of research
Infectious Diseases · Virology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, HIV Research and Treatment, and Viral gastroenteritis research and epidemiology.
<scp>T1</scp>‐Hyperintense Cystic Renal Masses: <scp>MR</scp> Subtraction Imaging May Improve Interobserver Agreement and Diagnostic Performance in the Bosniak Classification
An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation
Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids
The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
Engineered trimeric ACE2 binds viral spike protein and locks it in “Three-up” conformation to potently inhibit SARS-CoV-2 infection
Development of oncolytic virotherapy: from genetic modification to combination therapy
Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit
Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases
A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD
A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD
Chemical and structural analysis of a photoactive vertebrate cryptochrome from pigeon
Efficacy and mechanism of cGAMP to suppress Alzheimer’s disease by elevating TREM2
Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains
Advancements in Developing Strategies for Sterilizing and Functional HIV Cures